Olsenella uli

(aka Lactobacillus uli)

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Olsenella uli, (aka Lactobacillus uli), is a Gram-positive, non-spore-forming, microaerophilic, non-motile, rod-shaped bacterium. It has been detected in at least 6 gut microbiome compilation studies or metastudies. The DNA G+C content is 64%. Olsenella uli is probably a rare gut coloniser. (Dewhirst2001; Kraatz2011; Li2015; Olsen1991)



  • This organism has been recovered from human faeces. The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread. It is an opportunistic pathogen. A possible gut commensal.
    • GENERAL CHARACTERISTICS (Dewhirst2001); (Kraatz2011); (Li2015); (Olsen1991);
    Character Response
  • Substrates hydrolysed or digested:
  • aesculin; arginine; mucin;
  • ±
  • Strain-dependent hydrolysis or digestion:
  • milk;
  • 🧂
  • Salt tolerance:
  • doesn't tolerate 6.5% salt;
  • 🌡
  • Temperature tolerance:
  • grows at 37℃; strain-variable at 45(d);
  • H+
  • Acid from carbohydrates usually produced:
  • fructose; glucose; mannose; glycogen; starch; maltose; sucrose;
  • ±
  • Strain-dependent acid from carbs:
  • lactose; salicin;
  • ⥅
  • Substrates assimilated or utilised:
  • mucin;
  • Active enzymes:
  • Ala arylamidase; acid phosphatase; Arg arylamidase; arginine dihydrolase; β-glucosidase; Gly arylamidase; His arylamidase; Leu arylamidase; Leu-Gly arylamidase; Phe arylamidase; Pro arylamidase; Ser arylamidase;
  • ±
  • Strain-dependent active enzymes:
  • naphthol-ASBI-P;
    • SPECIAL FEATURES (Kraatz2011); (Li2015); (Olsen1991);
    Character Response
  • ✓
  • Metabolites produced:
  • formate; acetate; lactate (major);
  • ✗
  • Metabolites not produced:
  • ammonia; indole;
  • ✗
  • Nitrate:
  • not reduced
    • RESPONSE TO ANTIBIOTICS (Goldstein2013); (Citron2012a); (Goldstein2005); (Citron2001); (Olsen1991);
    Class Active Resistant
  • Penicillins:
  • amoxicillin-clavulanic acid; ampicillin; ampicillin-sulbactam; ertapenem; imipenem; penicillin; penicillin G; piperacillin-tazobactam;
  • Cephalosporins:
  • cefoxitin;
  • Macrolides:
  • erythromycin; pristinamycin; quinupristin-dalfopristin;
  • Quinolines:
  • levofloxacin; moxifloxacin;
  • Heterocycles:
  • metronidazole;
  • Vancomycins:
  • vancomycin;
  • Miscellaneous antibiotics:
  • clindamycin; pristinamycin;

  • Lagier, J.-C., Armougom, F., Million, M., Hugon, P., Pagnier, I., Robert, C., Bittar, F., Fournous, G., Gimenez, G., Maraninchi, M., Trape, J.-F., Koonin, E. V., La Scola, B., & Raoult, D. (2012). Microbial culturomics: paradigm shift in the human gut microbiome study. Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 18(12), 1185–1193.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Actinobacteria Class:  Coriobacteriia Order:  Coriobacteriales Family:  Atopobiaceae Genus:  Olsenella Alt. name:  Lactobacillus uli Gram stain:  + O2 Relation.:  microaerophilic Spore:  No spore Motility:  Sessile Morphology:  Rod
    Health:  Unknown
    Source:  human faeces
    DNA G+C(%):  64
    Mid T(℃):  37(+)
    High T(℃):  45(d)
    NaCl >6%:  6.5(neg)
    		Aesculin:  + Urea:  neg Gelatin:  neg Starch:  vr Arginine:  d(+) DNA:  neg Hippurate:  neg Milk:  curdle(d(neg)) Meat:  neg
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg Fructose:  + Glucose:  + Mannose:  + Rhamnose:  neg Ribose:  neg Cellubiose:  neg Lactose:  d(neg) Maltose:  + Melezitose:  neg Melibiose:  neg Sucrose:  + Trehalose:  neg Amygdalin:  neg Aesculin:  neg Glycogen:  + Inulin:  neg Starch:  + Erythritol:  neg Glycerol:  neg Mannitol:  neg Sorbitol:  neg Salicin:  d
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Catalase:  neg Urease:  neg G6PDH6PGDH:  neg α-Arab:  neg Ac-β-glcamnd:  neg α-Fucosidase:  neg α-Galactosidase:  neg β-Galactosidase:  neg α-Glucosidase:  neg β-Glucosidase:  + β-Glucuronidase:  neg α-Mannosidase:  neg ArgDH:  + Chymotrypsin:  neg GluDC:  neg Trypsin:  neg AlanineAA:  + ArgAA:  + GluGluAA:  neg GlyAA:  + HisAA:  + LeuAA:  + LeuGlyAA:  + ProAA:  + PyrrolidAA:  neg PheAA:  + PyrogluAA:  neg SerAA:  + TyrAA:  vr AlkalineP:  vr AcidP:  + DNAse:  neg Esterase(C4):  neg EstLip(C8):  neg Lipase(C14):  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Formate:  + Acetate:  + Lactate:  Major(+) Ammonia:  neg Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    Augmentin:  S(MIC50): 0.125, MIC90: 0.5, RNG: (≤0.015-2)
    ampicillin:  S(MIC50): 0.125, MIC90: 0.5, RNG: (0.03-1)
    amp-sulb:  S(MIC50): 0.125, MIC90: 1, RNG: (0.06-1)
    penicillin:  S(MIC50): 0.125, MIC90: 0.5, RNG: (0.06–1)
    penicillin_G:  S(MIC50): 0.125, MIC90: 0.5, RNG: (≤0.03-1)
    piper-taz:  S(MIC50): 0.25, MIC90: 1, RNG: (≤0.03-1)
    ertapenem:  S(0.06/0.5)
    imipenem:  S(MIC50): 0.06, MIC90: 0.25, RNG: (0.015–0.5)
    cefalexin:  Var(MIC50): 1, MIC90: >32, RNG: (0.25->32)
    cefoxitin:  S(MIC50): 4, MIC90: 16, RNG: (0.06–16)
    azithromycin:  Var(MIC50): 0.06, MIC90: 8, RNG: (≤0.03->32)
    erythromycin:  S(MIC50): ≤0.03, MIC90: 2, RNG: (≤0.03-16)
    fidaxomicin:  Var(MIC50): 2, MIC90: >32, RNG: (0.125–>32)
    clarithromycin:  Var(MIC50): 0.5, MIC90: >32, RNG: (0.06–>32)
    pristinamycin:  S(MIC50): 0.12, MIC90: 0.25, RNG: (0.03–2)
    quin-dalf:  S(MIC50): 0.25, MIC90: 1, RNG: (0.125-4)
    roxithromycin:  Var(MIC50): 2, MIC90: >32, RNG: (0.06–>32)
    telithromycin:  Var(MIC50): 0.06, MIC90: >32, RNG: (0.06–>32)
    linezolid:  Var(MIC50): 4, MIC90: 8, RNG: (1-8)
    ciprofloxacin:  Var(MIC50): 1, MIC90: >8, RNG: (≤0.5->8)
    levofloxacin:  S(MIC50): 2, MIC90: 4, RNG: (0.125–8)
    moxifloxacin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.06–8)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    tetracycline:  Var(MIC50): 1, MIC90: 16, RNG: (0.125-32)
    vancomycin:  S(MIC50): 1, MIC90: 4, RNG: (0.25-8)
    metronidazole:  R(MIC50): 32, MIC90: >32, RNG: (0.125->32)
    clindamycin:  S(MIC50): ≤0.03, MIC90: 0.5, RNG: (≤0.03->32)
    daptomycin:  Var(MIC50): 4, MIC90: >32, RNG: (0.25->32)

    References

    SPECIFIC REFERENCES FOR OLSENELLA ULI
  • Dewhirst2001 - Characterization of novel human oral isolates and cloned 16S rDNA sequences that fall in the family Coriobacteriaceae: description of olsenella gen. nov., reclassification of Lactobacillus uli as Olsenella uli comb. nov. and description of Olsenella profusa sp. nov.
  • Kraatz2011 - Olsenella umbonata sp. nov., a microaerotolerant anaerobic lactic acid bacterium from the sheep rumen and pig jejunum, and emended descriptions of Olsenella, Olsenella uli and Olsenella profusa.
  • Li2015 - Olsenella scatoligenes sp. nov., a 3-methylindole- (skatole) and 4-methylphenol- (p-cresol) producing bacterium isolated from pig faeces.
  • Goldstein2013 - In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.
  • Citron2012a - Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.
  • Goldstein2005 - Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli.
  • Citron2001 - Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.
  • Olsen1991 - Lactobacillus uli sp. nov. and Lactobacillus rimae sp. nov. from the Human Gingival Crevice and Emended Descriptions of Lactobacillus minutus and Streptococcus parvulus.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR OLSENELLA ULI
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • New2022 - Collective effects of human genomic variation on microbiome function.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................
    • Added: April 08, 2021